Eleven pharmaceutical companies recently settled a class action in U.S. District Court in Massachusetts concerning their alleged inflation of prescription drug wholesale prices for $125 million.
In the litigation, consumers and insurance companies accused the companies of fraudulently inflating published average wholesale drug prices. Those wholesale prices led to higher consumer and insurance company payments for branded and generic drugs used to treat serious illnesses like cancer and HIV. In re: Pharmaceutical Industry Average Wholesale Price Litigation, M.D.L. No. 1456, No. 01-12257 (D. Mass).
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
